Request Samples

This site is intended for US Healthcare Professionals only.

KERENDIA® (finerenone) logo
CKD ASSOCIATED WITH T1D

This site is intended for US Healthcare Professionals only.

Elevated UACR can signal increased risk of disease progression

Patient Profiles

Icon of a kidney and blood drop

THE FIRST TREATMENT APPROVED FOR YOUR ADULT PATIENTS WITH CKD ASSOCIATED WITH T1D IN 30+ YEARS1,2 
KERENDIA reduces UACR, which is expected to slow CKD progression1,3

Patient Profiles

In your adult patients with CKD associated with T1D1

Elevated UACR can signal increased risk of disease progression3,4

Every patient touchpoint is an opportunity to start KERENDIA

    Ron (UACR 200)

    Even on standard of care

    Ron’s persistently elevated UACR puts him at elevated risk of CKD progression

    Not a real patient.

    Age: 56

    Medical history3,5:

    • T1D diagnosed at age 21
      (35-year duration)

    Comorbidities3,5:

    • Coronary artery disease
    • Controlled hypertension

    Current treatments3,5:

    • ARB stable dose
    • Loop diuretic
    • Metformin
    • SGLT2i
    • Statin

    Current labs/imaging3,5,6:

    • eGFR: 54 mL/min/1.73 m2
    • UACR: 200 mg/g
    • Serum potassium: 4.5 mEq/L
    • HbA1c: 7.6%
    Ron patient profile portrait

    Not a real patient.

    Age: 56

    Medical history3,5:

    • T1D diagnosed at age 21
      (35-year duration)

    Comorbidities3,5:

    • Coronary artery disease
    • Controlled hypertension

    Current treatments3,5:

    • ARB stable dose
    • Loop diuretic
    • Metformin
    • SGLT2i
    • Statin

    Current labs/imaging3,5,6:

    • eGFR: 54 mL/min/1.73 m2
    • UACR: 200 mg/g
    • Serum potassium: 4.5 mEq/L
    • HbA1c: 7.6%

    Ron’s UACR indicates he is at 37x increased risk of kidney failure* compared to patients with preserved eGFR and UACR <10 mg/g.4

    Hospital icon

    *With replacement therapy.4

    ARB=angiotensin receptor blocker; CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; HbA1c=glycated hemoglobin; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T1D=type 1 diabetes; UACR=urine albumin-to-creatinine ratio.

    Help your patients access KERENDIA with ease

    Sample Letters of Appeal
    Ellen (UACR 549)

    Even on standard of care

    Ellen remains at high risk of CKD progression due to her persistently elevated UACR

    Not a real patient.

    Age: 42

    Medical history3,5:

    • T1D diagnosed at age 14 
      
(28-year duration)

    Comorbidities3,5:

    • Controlled hypertension

    Current therapies3,5:

    • Hybrid closed-loop insulin
      pump therapy
    • ACEi
    • CCB
    • Statin

    Current labs/imaging3,5,6:

    • eGFR: 82 mL/min/1.73 m2
    • UACR: 549 mg/g
    • Serum potassium: 4.4 mEq/L
    • HbA1c: 7.2%
    Ellen patient profile portrait

    Not a real patient.

    Age: 42

    Medical history3,5:

    • T1D diagnosed at age 14
      
(28-year duration)

    Comorbidities3,5:

    • Controlled hypertension

    Current therapies3,5:

    • Hybrid closed-loop insulin
      pump therapy
    • ACEi
    • CCB
    • Statin

    Current labs/imaging3,5,6:

    • eGFR: 82 mL/min/1.73 m2
    • UACR: 549 mg/g
    • Serum potassium: 4.4 mEq/L
    • HbA1c: 7.2%

    Ellen’s UACR indicates she is at 27x increased risk of kidney failure* compared to patients with preserved eGFR and UACR <10 mg/g.4

    Hospital icon

    *With replacement therapy.4

    ACEi=angiotensin-converting enzyme inhibitor; CCB=calcium channel blocker; CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; HbA1c=glycated hemoglobin; T1D=type 1 diabetes; UACR=urine albumin-to-creatinine ratio.

    Help your patients access KERENDIA with ease

    Sample Letters of Appeal
    Efficacy & Safety Dosing
    References:
    1. KERENDIA® (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2026.
    2. Sridhar VS, et al. Diabetologia. 2024;67(1):3-18.
    3. Heerspink HJL, et al. N Engl J Med. 2026;394(10):947-957.
    4. Grams ME, et al. JAMA. 2023;330(13):1266-1277.
    5. Heerspink HJL, et al. N Engl J Med. 2026;394(10):947-957 [supplemental].
    6. Heerspink HJL, et al. Nephrol Dial Transplant. 2026;41(3):556-565.

    INDICATIONS:

    KERENDIA (finerenone) 10 mg, 20 mg tablets is indicated to:

    • reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D)
    • reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes (T1D)

    EXPANDCOLLAPSE

    EXPANDCOLLAPSE

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS:

    • Hypersensitivity to any component of this product
    • Concomitant use with strong CYP3A4 inhibitors
    • Patients with adrenal insufficiency

    WARNINGS AND PRECAUTIONS:

    • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5 mEq/L.

      Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.

    MOST COMMON ADVERSE REACTIONS:

    • The adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3%), and hyponatremia (1.3% vs 0.7%).

    DRUG INTERACTIONS for KERENDIA 10 mg, 20 mg:

    • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.
    • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor, and adjust KERENDIA dosage as appropriate.
    • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers.

    USE IN SPECIFIC POPULATIONS:

    • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment.
    • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B).
    Please see the full Prescribing Information for KERENDIA.

    © 2026 Bayer. All rights reserved. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer. All other trademarks are the property of their respective owners. Last updated 09/26

    You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.